Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease
スポンサーリンク
概要
- 論文の詳細を見る
We enrolled 11 patients with refractory graft-versus-host disease (GVHD) in a prospective trial evaluating the efficacy of mycophenolate mofetil (MMF). Four (67%) of the 6 patients with acute GVHD and all 5 patients with chronic GVHD responded to MMF. Ten (91%) of the 11 patients were able to decrease steroid use (median decrease, 86%; range, 25%-l00%). After a median follow-up of 18 months (range, 1-65 months), 7 patients (64%) remained alive. The adverse events were infectious complications (36%), diarrhea (27%), and neutropenia (18%); the only patient discontinuing MMF did so because of grade 4 neutropenia. This preliminary study suggests that MMF is a well-tolerated agent and has a beneficial effect in the treatment of refractory acute and chronic GVHD. ©2006 The Japanese Society of Hematology.
- 日本血液学会 = Japanese Society of Hematologyの論文
- 2006-01-00
日本血液学会 = Japanese Society of Hematology | 論文
- Reactive peripheral blood plasmacytosis in a patient with acute hepatitis A
- Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stein cell transplan
- Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease
- Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation
- Primary tracheal lymphoma: Case report and literature review